These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

125 related articles for article (PubMed ID: 35172062)

  • 1. Audio Interview: A New Antiviral against Covid-19.
    Rubin EJ; Baden LR; Morrissey S
    N Engl J Med; 2022 Feb; 386(7):e25. PubMed ID: 35172062
    [No Abstract]   [Full Text] [Related]  

  • 2. Nirmatrelvir-ritonavir for COVID-19.
    McDonald EG; Lee TC
    CMAJ; 2022 Feb; 194(6):E218. PubMed ID: 35115376
    [No Abstract]   [Full Text] [Related]  

  • 3. Caution required with use of ritonavir-boosted PF-07321332 in COVID-19 management.
    Heskin J; Pallett SJC; Mughal N; Davies GW; Moore LSP; Rayment M; Jones R
    Lancet; 2022 Jan; 399(10319):21-22. PubMed ID: 34973713
    [No Abstract]   [Full Text] [Related]  

  • 4. From Positive to Negative to Positive Again-The Mystery of Why COVID-19 Rebounds in Some Patients Who Take Paxlovid.
    Rubin R
    JAMA; 2022 Jun; 327(24):2380-2382. PubMed ID: 35675094
    [No Abstract]   [Full Text] [Related]  

  • 5. Paxlovid for treatment of COVID-19.
    Med Lett Drugs Ther; 2022 Jan; 64(1642):9-10. PubMed ID: 35134040
    [No Abstract]   [Full Text] [Related]  

  • 6. A National Strategy for COVID-19 Medical Countermeasures: Vaccines and Therapeutics.
    Borio LL; Bright RA; Emanuel EJ
    JAMA; 2022 Jan; 327(3):215-216. PubMed ID: 34989782
    [No Abstract]   [Full Text] [Related]  

  • 7. Bad news for Paxlovid? Resistance may be coming.
    Service RF
    Science; 2022 Jul; 377(6602):138-139. PubMed ID: 35857562
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Antiviral pills could change pandemic's course.
    Couzin-Frankel J
    Science; 2021 Nov; 374(6569):799-800. PubMed ID: 34762459
    [No Abstract]   [Full Text] [Related]  

  • 9. Nirmatrelvir-Ritonavir and Viral Load Rebound in Covid-19.
    Anderson AS; Caubel P; Rusnak JM;
    N Engl J Med; 2022 Sep; 387(11):1047-1049. PubMed ID: 36069818
    [No Abstract]   [Full Text] [Related]  

  • 10. Rebound of SARS-CoV-2 Infection after Nirmatrelvir-Ritonavir Treatment.
    Charness ME; Gupta K; Stack G; Strymish J; Adams E; Lindy DC; Mohri H; Ho DD
    N Engl J Med; 2022 Sep; 387(11):1045-1047. PubMed ID: 36069968
    [No Abstract]   [Full Text] [Related]  

  • 11. An oral SARS-CoV-2 M
    Owen DR; Allerton CMN; Anderson AS; Aschenbrenner L; Avery M; Berritt S; Boras B; Cardin RD; Carlo A; Coffman KJ; Dantonio A; Di L; Eng H; Ferre R; Gajiwala KS; Gibson SA; Greasley SE; Hurst BL; Kadar EP; Kalgutkar AS; Lee JC; Lee J; Liu W; Mason SW; Noell S; Novak JJ; Obach RS; Ogilvie K; Patel NC; Pettersson M; Rai DK; Reese MR; Sammons MF; Sathish JG; Singh RSP; Steppan CM; Stewart AE; Tuttle JB; Updyke L; Verhoest PR; Wei L; Yang Q; Zhu Y
    Science; 2021 Dec; 374(6575):1586-1593. PubMed ID: 34726479
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Treatment of COVID-19 in high-risk outpatients.
    Med Lett Drugs Ther; 2022 Feb; 64(1643):e1. PubMed ID: 35134051
    [No Abstract]   [Full Text] [Related]  

  • 13. The Latest Research About Paxlovid: Effectiveness, Access, and Possible Long COVID Benefits.
    Rubin R
    JAMA; 2024 Oct; 332(13):1040-1042. PubMed ID: 39240544
    [TBL] [Abstract][Full Text] [Related]  

  • 14. COVID-19 Therapeutics for Nonhospitalized Patients.
    Gandhi RT; Malani PN; Del Rio C
    JAMA; 2022 Feb; 327(7):617-618. PubMed ID: 35029659
    [No Abstract]   [Full Text] [Related]  

  • 15. Oral Nirmatrelvir for High-Risk, Nonhospitalized Adults with Covid-19.
    Hammond J; Leister-Tebbe H; Gardner A; Abreu P; Bao W; Wisemandle W; Baniecki M; Hendrick VM; Damle B; Simón-Campos A; Pypstra R; Rusnak JM;
    N Engl J Med; 2022 Apr; 386(15):1397-1408. PubMed ID: 35172054
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Why scientists are racing to develop more COVID antivirals.
    Kozlov M
    Nature; 2022 Jan; 601(7894):496. PubMed ID: 35064230
    [No Abstract]   [Full Text] [Related]  

  • 17. COVID is here to stay: countries must decide how to adapt.
    Nature; 2022 Jan; 601(7892):165. PubMed ID: 35013606
    [No Abstract]   [Full Text] [Related]  

  • 18. The global COVID-19 treatment divide.
    Usher AD
    Lancet; 2022 Feb; 399(10327):779-782. PubMed ID: 35219388
    [No Abstract]   [Full Text] [Related]  

  • 19. [Molnupiravir or nirmatrelvir-ritonavir reduce the likelihood of hospitalization and mortality in immunocompromised patients with Covid-19.].
    Kurotschka PK; Ebell MH; Serafini A
    Recenti Prog Med; 2024 Sep; 115(9):399. PubMed ID: 39269352
    [No Abstract]   [Full Text] [Related]  

  • 20. Hundreds of COVID trials could provide a deluge of new drugs.
    Ledford H
    Nature; 2022 Mar; 603(7899):25-27. PubMed ID: 35233098
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 7.